Researchers at the University Medical Centre Freiburg report that a light-based blood treatment significantly reduces the inflammatory side effects of modern cancer immunotherapies. The procedure is based on extracorporeal photopheresis: patients have blood drawn, their leukocytes are treated outside the body with a light-sensitive substance and then irradiated with UV-A light, before the cells are reinfused. According to the Freiburg clinic, these procedures led to partial or complete improvement in symptoms in 96 per cent of assessable cases among 30 patients over twelve weeks in a clinical Phase II study ([uniklinik-freiburg.de](https://www.uniklinik-freiburg.de/presse/pressemitteilungen/detailansicht/7023-freiburger-entdeckung-macht-krebsimmuntherapie-vertraeglicher.html?utm_source=openai))
The group’s earlier work further explains the mechanism by which the light treatment dampens the inflammatory response: according to the findings, the body’s own fat-metabolism molecule adiponectin plays an important role in the immunomodulatory effect after the treated cells are exposed to UV-A. Laboratory and preclinical findings had already shown that light-controlled interventions can alter immune responses in a targeted way and make tumour microenvironments less suppressive. Such approaches range from photoimmunotherapies and optogenetic methods to nanoinducible switches; the Freiburg paper now links a clinical application with molecular findings. ([cibss.uni-freiburg.de](https://www.cibss.uni-freiburg.de/de/news/uv-licht%20bestrahlte%20blutzellen-2?utm_source=openai))
The treatment is not the same as conventional systemic therapies. Instead, it uses a procedure already established in specialist areas of transfusion medicine—extracorporeal photopheresis—and applies it to immune-mediated complications of treatment. According to the study team, the anti-tumour effectiveness of immunotherapy was maintained; the explicit aim was to ease serious side effects without jeopardising the success of cancer treatment. The press release did not cite specific measures of cancer-treatment effectiveness as primary endpoints of the Phase II study, and further randomised trials are needed. ([uniklinik-freiburg.de](https://www.uniklinik-freiburg.de/presse/pressemitteilungen/detailansicht/7023-freiburger-entdeckung-macht-krebsimmuntherapie-vertraeglicher.html?utm_source=openai))
In practice, the results point to a possible additional treatment option for patients with treatment-related, immune-mediated inflammation. According to the statement, the Freiburg research group and other teams in Germany are in discussions with regulatory authorities and review bodies to clarify areas of use and regulations; a specific treatment system that is generally available remains subject to further assessment. Until then, the results should be regarded as promising, but not interpreted as a general recommendation for everyone affected. ([uniklinik-freiburg.de](https://www.uniklinik-freiburg.de/presse/pressemitteilungen/detailansicht/7023-freiburger-entdeckung-macht-krebsimmuntherapie-vertraeglicher.html?utm_source=openai))
Editor: Clara Simonichek (Article created with AI assistance).